The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.16205 ↗Kurz gefasst
Klinische Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Chandrali S Bhattacharya und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD…. Hauptthemen laut MEDLINE: Peroxidase, Enzyme Inhibitors, Renal Insufficiency. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Aims
Mitiperstat is a novel, highly potent myeloperoxidase inhibitor being evaluated in patients with cardio‐metabolic disease (phase 2). These patients often have impaired renal function, which may affect mitiperstat pharmacokinetics. This study assessed mitiperstat pharmacokinetics, safety and tolerability in participants with severe renal impairment and normal renal function, to inform inclusion of participants with estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m 2 in phase 3.
Methods
Participants with severe renal impairment (eGFR ≥15 and
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
- Early Clinical Development, Research and Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
- Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
- Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- Patient Safety, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
- Biometrics, Late Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
ORCID-Profile: Mikael Sunnåker, Hans Ericsson
Förderung
- AstraZeneca
Zitieren
APA
Bhattacharya, C. S., Pizzato, P. E., Heijer, M., Sunnåker, M., Holden, J., Trebski, M., Nelander, K., Ali, H., Genov, D. K., Aurell, M., Collén, A., & Ericsson, H. (2024). The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16205
Vancouver
Bhattacharya CS, Pizzato PE, Heijer M, Sunnåker M, Holden J, Trebski M, et al. The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16205
BibTeX
@article{Bhattacharya2024,
author = {Bhattacharya, Chandrali S and Pizzato, Patricia Ely and Heijer, Maria and Sunnåker, Mikael and Holden, Julie and Trebski, Monika and Nelander, Karin and Ali, Hodan and Genov, Diyan K and Aurell, Malin and Collén, Anna and Ericsson, Hans},
title = {The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.16205}
}
EUVIMED